Review Article

Targeting the Mechanisms of Resistance to Chemotherapy and Radiotherapy with the Cancer Stem Cell Hypothesis

Ryan Morrison,1 Stephen M. Schleicher,2 Yunguang Sun,2 Kenneth J. Niermann,2 Sungjune Kim,2 Daniel E. Spratt,2 Christine H. Chung,3 and Bo Lu2

1 Joan C. Edwards School of Medicine, Marshall University, Huntington, WV 25701, USA
2 Department of Radiation Oncology, Vanderbilt University School of Medicine, Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center Nashville, 1301 22nd Avenue South, B-902 TVC, Nashville, TN 37232-5671, USA
3 Department of Hematology/Oncology, Vanderbilt University School of Medicine, Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center Nashville, 1301 22nd Avenue South, B-902 TVC, Nashville, TN 37232-5671, USA

Correspondence should be addressed to Bo Lu, bo.lu@vanderbilt.edu

Received 5 July 2010; Accepted 14 September 2010

Academic Editor: Shih Hwa Chiou

Copyright © 2011 Ryan Morrison et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Despite advances in treatment, cancer remains the 2nd most common cause of death in the United States. Poor cure rates may result from the ability of cancer to recur and spread after initial therapies have seemingly eliminated detectable signs of disease. A growing body of evidence supports a role for cancer stem cells (CSCs) in tumor regrowth and spread after initial treatment. Thus, targeting CSCs in combination with traditional induction therapies may improve treatment outcomes and survival rates. Unfortunately, CSCs tend to be resistant to chemo- and radiation therapy, and a better understanding of the mechanisms underlying CSC resistance to treatment is necessary. This paper provides an update on evidence that supports a fundamental role for CSCs in cancer progression, summarizes potential mechanisms of CSC resistance to treatment, and discusses classes of drugs currently in preclinical or clinical testing that show promise at targeting CSCs.

1. Introduction

Individualized cancer treatment has been an attractive concept since the beginning of cancer research. Breakthroughs in research have allowed the characterization of malignancies according to their unique gene expression, which has allowed the pragmatic targeting of many cancer types based on their specific gene expression patterns. For example, trastuzumab improves the overall and progression-free survival in human epidermal receptor 2- (Her2-) positive breast cancer [1–3]. The receptor-specific monoclonal antibodies bevacizumab [4, 5] and cetuximab [6] have shown remarkable outcome in vascular growth factor receptor- (VEGF- ) positive and epidermal growth factor receptor (EGFR)-positive cancer, respectively. Examples of other targeted therapies [7–9] are shown in Table 1. Indeed, the age of individualized cancer therapy has begun.

Individualized profiling and targeting systems provide novel tools to improve both prognostic accuracy and individualized treatment for patients [10]. In addition, each of the classical pillars of cancer therapy—(1) surgical resection, (2) chemotherapy, and (3) radiation therapy—has made significant technological strides, and numerous clinical studies have improved our ability to effectively apply and combine these modalities. Vaccines that prevent the spread of the human papilloma virus (HPV) promise to dramatically reduce cervical cancer; conversely, viruses are being developed that directly attack carcinogenic cells [11]. Advancements such as functional imaging, magnetic resonance imaging, immunohistochemistry, and flow cytometry have recently refined our ability to tease out, subdivide, prognosticate, and define the myriad of permutations in this uniquely complex and malignant disease. A growing arsenal of prevention strategies and screening technologies has allowed physicians to diagnose and treat cancer earlier in its progression than ever before. All of these evolving modalities and strategies to manage cancer have helped result in a pattern of continuously dwindling cancer-related morbidity and mortality in the United States [12].
represents a promising new front in the war on cancer. This hypothesis has helped explain how cancer might recur and metastasize despite e... small fraction of progenitor cells [15, 16]. These cancer cells... that retain their normal stem cell properties of self-renewal... and pluripotency are often referred to as CSCs. Within the... tumors may acquire resistance to chemotherapy and radiation [36, 37]. Multiple investigators have demonstrated the ability of CSCs to develop resistance traits after induction chemo- and radiation therapy.

Evidence suggests that CSCs are highly heterogeneous [38, 39]. This heterogeneity may be responsible for the evolution of resistance to first-line therapies in recurrent cancer since treatment-resistant cells within a heterogeneous tumor population may be selected for during induction therapy. The outcome may be a more aggressive and treatment-resistant malignant recurrence [36]. In addition, CSC heterogeneity may make the pharmacological eradication of the entire CSC population difficult since these cells may exhibit variable expression of drug-targeted genetic markers.

### Table 1: Update on clinical trials for CSC molecular targets.

| Target  | Drug      | Cancer          | Phase | http://clinicaltrials.gov/Identifier | Sponsor                          |
|---------|-----------|-----------------|-------|----------------------------------|----------------------------------|
| Eph     | Resveratrol| Colon           | I, II | NCT00256334                      | University of California, Irvine |
| Notch   | MK0752    | Breast          | I     | NCT00106145                      | Merck                            |
|         |           | Pancreatic      | I, II | NCT01098344                      | Cancer Research UK               |
|         | RO4929097 | Renal cell      | II    | NCT01141569                      | University Health Network, Toronto |
|         | PF-03084014| Leukemia        | I     | NCT00878189                      | Pfizer                           |
| Hedgehog| GDC-0449  | Solid tumors    | I     | NCT00968981                      | Genentech                        |
|         |           | Colorectal      | II    | NCT00636610                      | Genentech                        |
|         | PF-04449913| Hematologic     | I     | NCT00953758                      | Pfizer                           |
|         | BMS-833923| Basal cell      | I     | NCT00670189                      | Bristol-Myers Squibb             |
|         | LDE225    | Medulloblastoma | I     | NCT00880308                      | Novartis                         |

However, despite this progress, cancer remains the 2nd most common cause of death in the United States [13]. Our continuing inability to cure cancer is largely attributed to the ability of cancer cells to spread and repopulate after initial therapies have eliminated all detectable signs of disease. New interventions that reduce this capacity could have a far-reaching impact on our ability to prevent recurrences, extend survival, and cure many types of cancer. Thus, better understanding the mechanisms of cancer progression for the development of antirepopulation therapies is likely to offer significant clinical benefit. The cancer stem cell (CSC) hypothesis has emerged within this line of investigation. This hypothesis has helped explain how cancer might recur and metastasize despite effective initial treatment and thus represents a promising new front in the war on cancer.

### 2. The CSC Hypothesis

A paradigm shift in our understanding of cancer tumorigenesis emerged in 1994 when John Dick and colleagues demonstrated that human acute myeloid leukemia (AML) has a hierarchical organization that originates from a primitive hematopoietic cell [14]. This popularized a concept first proposed over a century ago: that cancer growth within a given neoplastic process may be dependent upon only a small fraction of progenitor cells [15, 16]. These cancer cells that retain their normal stem cell properties of self-renewal and pluripotency are often referred to as CSCs. Within the framework of the CSC hypothesis, normally dormant stem cells may inadvertently acquire tumorigenic DNA mutations and become CSCs which inappropriately begin dividing and direct the neoplastic process. Multiple studies have recently provided compelling support of the CSC hypothesis [17–19].

Despite controversies surrounding the CSC hypothesis [20, 21], substantial evidence has emerged that supports its role in cancer including AML [22], brain [23], breast [24], colon [25], head and neck [26], lung [27], liver [28], melanoma [29], pancreatic [30], prostate [31], and squamous cell [32] cancer (Figure 1). At least 15 drugs designed to exploit the CSC hypothesis have entered clinical trials [33]. However, the CSC hypothesis has not been fully established and will likely evolve as unknown molecular targets capable of promoting tumorigenesis continue to be discovered [34]. Moreover, the translation from the theoretical benefit of CSC eradication into its actual clinical benefit has to be experimentally demonstrated. Another poorly understood nuance is that certain cancer types may be relatively independent of fractional CSC populations, operating more consistently with classical stochastic or clonal evolution models [35]. Although there are limitations to the CSC hypothesis, it is evident that cancer often possesses functionally defined CSCs, and is likely to be at least partially dependent on CSCs for growth and survival.

In cancer types where neoplastic growth and differentiation depend on CSCs, complete eradication of this population may be curative. Furthermore, agents that force CSCs to rapidly differentiate *en masse* within such cancer types may limit disease progression. Alternatively, suppressing residual CSCs after initial tumor debulking may sustain remissions and extend the progression-free survival of patients receiving CSC suppressive therapy. Considering these distinct therapeutic potentials of targeting CSCs, it appears that CSC-targeted therapies could be an effective complement to traditional treatment approaches such as surgery, chemotherapy, and radiation therapy. Indeed, it is possible that these traditional strategies leave behind residual CSCs which are capable of spreading and regenerating tumors, leading to cancer recurrence and metastasis. Moreover, these recurring tumors often acquire resistance to chemotherapy and radiation [36, 37]. Multiple investigators have demonstrated the ability of CSCs to develop resistance traits after induction chemo- and radiation therapy.

Evidence suggests that CSCs are highly heterogeneous [38, 39]. This heterogeneity may be responsible for the evolution of resistance to first-line therapies in recurrent cancer since treatment-resistant cells within a heterogeneous tumor population may be selected for during induction therapy. The outcome may be a more aggressive and treatment-resistant malignant recurrence [36]. In addition, CSC heterogeneity may make the pharmacological eradication of the entire CSC population difficult since these cells may exhibit variable expression of drug-targeted genetic markers.
This task is complicated by the possibility that cancer may exhibit fluctuating phenotypes, frequencies, and biological properties within an individual patient [40]. Furthermore, existing microenvironmental signaling pathways may recruit or promote CSC functions, perhaps through neoplastic clonal dedifferentiation processes [40, 41]. Until these challenges are overcome, CSC-targeting therapies will not reach their full potential. Regardless, research surrounding the CSC hypothesis has already helped generate numerous potential pharmacological interventions, and combinations of these CSC-specific therapeutic approaches with traditional cancer treatment strategies may show synergistic benefits since their mechanisms of action are distinct and complementary.

3. Frequent Cancer Recurrence May Be due to the Preferential Killing of Differentiated Cells While Leaving CSCs behind

As previously mentioned, cancer recurrence may be partly due to the fact that conventional therapies such as chemo- and radiation therapy fail to specifically target CSCs. Instead, these therapies likely enrich CSC populations by preferentially killing differentiated cancer cells that had little potential to sustain cancer growth. Numerous studies indicate that CSCs are resistant to chemo- and radiotherapy and are therefore preferentially preserved when cancer cells are targeted by these approaches [15, 42–45]. Interestingly, during differentiation therapy for the treatment of acute promyelocytic leukemia (APML), all-transretinoic acid and arsenic trioxide are used to induce the differentiation of CSCs down their hematopoietic lineage. The outcome is dramatically reduced self-renewal capacity and extended patient survival [46]. The dramatic anticancer effects of combined modality differentiation therapy in leukemia also demonstrate how synergy between independent therapeutic approaches can achieve remarkable outcomes in cancer therapy [47]. Thus, differentiation treatment of APML serves to illustrate (1) the relative impotence of differentiated cells in cancer, (2) the potential therapeutic benefit of specifically targeting CSCs, and (3) the potential synergy between CSC-specific therapies and existing modalities.

4. The Detection and Identification of CSCs

In recent years, an effort has been made to successfully identify stem cells in multiple human malignancies, including hematological, breast, colorectal, brain, pancreatic, and maxillofacial cancer [22, 25, 32, 34, 36, 48–50]. Much attention has been directed to specific cell-surface proteins. Among these, CD133/prominin-1 is a cell-surface molecule thought to be a stem cell marker for multiple cancer types, including CNS, colon, hepatocellular, pancreatic, prostate, and renal cancer [51]. Eramo et al. demonstrated that freshly excised small cell and nonsmall cell lung cancers tissues contain a small subset of CD133-positive cells capable of generating long-term lung tumor spheres in vitro and differentiating into tumors in vivo. Matsumoto et al. elucidated a mechanistic relationship between CD133 and the hypoxia-inducible factor-1α (HIF-1α), a downstream molecule in the mammalian target of rapamycin (mTOR) cell signaling.
pathway, suggesting a role for mTOR in the regulation of CD133 expression [52].

In addition to cell-surface markers, many investigators have focused on the selective overexpression of certain genes normally present in progenitor cells. Leukemia cells, which have been transformed from the normally present “partially committed” cells responsible for physiological cellular maintenance, undergo mutations that result in self-perpetuated renewal capabilities. These cells can be identified by selective gene overexpression [24, 53–57]. In an attempt to link cellular pathways to gene expression patterns in lung CSCs, Stevenson et al. compiled and tested a model of 100 signature genes to determine embryonic stemness. Cells with a high embryonic stemness score were found to affect multiple cellular processes, including Ras, Myc, chromosomal instability, and cellular invasiveness [58]. Seo and colleagues demonstrated increased expression of 13 genes in side-population (SP) A549 nonsmall cell lung cancer cells, as compared to non-SP cells [59].

Interestingly, Glinsky has developed a novel clinical model to assess the relative “stemness” of cancer cells by quantifying gene expression signatures, and he has shown that this model may predict therapeutic outcomes. The “BMI1 pathway” algorithm is based on a collective signature of 9 individual gene characteristics: TEZ, EED pathway, Suz12/POLII, Suz12, Nanog/Sox2/Oct4, PcG-TF, BCD-TF, ESC pattern, and BMI1 pathway. This multifactorial model allowed the stratification of patients into high-risk and low-risk groups in a retrospective analysis of large cohorts of breast, prostate, lung, and ovarian cancer patients [60]. It remains to be confirmed whether an individual cellular marker can accurately identify normal stem cells or CSCs or whether a multifactorial phenotypic model is required.

5. Mechanisms of CSC Resistance to Chemotherapy and Radiation

CSCs have been found to exhibit a number of genetic and cellular adaptations that confer resistance to classical therapeutic approaches. These include relative dormancy/slow cell cycle kinetics, efficient DNA repair, high expression of multidrug-resistance-type membrane transporters, and resistance to apoptosis (Figure 2). Cancer often acquires resistance to chemo- or radiotherapy after nonlethal exposure [36]. This process likely represents the natural selection of resistant CSCs. Radiotherapy and most types of chemotherapy exert their antineoplastic function by disrupting cancer cell DNA integrity; therefore, it is possible that the oncogenic resistance of CSCs results from increased expression of DNA integrity-maintenance systems [61]. In addition, increased expression of drug efflux pumps may promote oncogenic resistance against cytotoxic chemotherapeutic agents [62, 63].

5.1. Resistance to DNA Damage within CSCs. Normal, non-cancerous stem cells exhibit well-fortified DNA mutation defense systems that typically serve to prevent mutation into carcinogenic CSCs. Unfortunately, when mutations that create CSCs do occur, the inherent defense systems of stem cells serve to protect them from DNA-targeting chemo- and radiation therapy. The chemo- and radioresistance of CSCs has now been demonstrated in numerous experiments [64], although the mechanisms underlying this resistance are not fully understood. In one experiment, radiation was shown to cause equal levels of damage to all cancer cells, but CSCs were able to repair this damage more rapidly [15].

One potential modulator of CSC resistance to DNA-targeting agents is the family of checkpoint kinases 1/2 (Chk1/2 kinases), which become activated after genotoxic stress and arrest the cell cycle to allow DNA repair. These kinases have higher basal and inducible activities in CSCs than in nonstem cells [65]. Supporting the role of Chk1/2 kinases in CSCs, Chk1/2 inhibitors partially reverse the resistance of glioblastoma CSCs to radiation-induced cell death [65, 66].

In addition to augmented DNA repair systems, CSCs may also exhibit changes in telomerase function, which allows resistance to chromosomal degradation in these rapidly dividing cells. Telomerase is a complex ribonucleoprotein enzyme that synthesizes and maintains telomeric repeats at the ends of chromosomal strands [67]. Sustained telomerase function is critical in conferring cellular immortality, as telomeres are otherwise shortened with each cell division, eventually triggering cellular senescence. Telomerase function was recently shown to be downregulated in brain CSCs, and several drugs that interfere with telomerase function are already in clinical trials, including arsenic trioxide, GRN163L, and vaccines [68–72].

5.2. Resistance to Drug Penetration into CSCs. An important component of the DNA integrity defense systems in normal stem cells is the relatively high expression of efflux transporters from the ATP-binding cassette (ABC) gene family [73]. These pumps allow normal stem cells to preserve their genome more effectively against chemical mutagens in an attempt to prevent carcinogenesis. Similar to the way that CSCs may derive resistance to DNA damage from the preexisting DNA repair systems in normal stem cells, CSCs may also derive resistance to chemical mutagens (e.g., chemotherapy) through the expression of drug efflux pumps in normal stem cells from which they were derived. Moreover, the relatively high expression of these transporters may be used to identify CSCs within a neoplasm [74]. Drugs that block the function of efflux transporters or that down-regulate their expression have the potential to overcome CSC chemoresistance. Although multidrug transporters are not likely to significantly influence the direct cytotoxicity of radiation-based therapies, chemotherapy or chemoradiation therapy may benefit from blockade of multidrug efflux pumps in CSCs.

5.3. Resistance to Apoptosis within CSCs. Resistance to therapy might also be conferred to CSCs through the activation of the Akt pathway [75, 76] and the overamplification of apoptosis inhibitor proteins. This was first demonstrated in chemoresistant hepatocellular carcinoma CSCs, which were found to preferentially activate Akt/PKB and bcl-2
cell survival pathways [77]. Moreover, inhibition of Akt by perifosine sensitizes CSCs to radiation-induced apoptosis [78]. This suggests that characterization of Akt and bcl-2 expression in CSCs may have significant clinical utility. FMS-like tyrosine kinase 3 (FLT3) receptor signaling is an important hematopoietic growth pathway upstream of Akt. FLT3 receptors are often mutated in AML and are associated with a high relapse rate and poor prognosis [79]. Inhibition of FLT3 signaling with CEP701 reduces the tumorigenicity of xenografts [80], and CEP 701 has reached phase 2 clinical trials [81].

The mitochondrial pathway of apoptosis is triggered by cytochrome c release and second mitochondrion-derived activator of caspase (Smac) activation [82]. Smac, in association with Direct Inhibitor of Apoptosis Binding Protein with low pi (Smac/DIABLO), promotes apoptosis via neutralization of inhibitor of apoptosis (IAP) proteins [82]. Most human cancers have high levels of IAPs, including the X-linked inhibitor of apoptosis protein (XIAP) isoform, which are associated with poor treatment responses [83]. Based on these observations, Vellanki et al. found that the inherent radiosensitivity of glioblastoma CSCs could be alleviated by promoting apoptosis with an XIAP inhibitor. Importantly, this treatment had no undesirable radiosensitizing effects on normal rat neurons or glial cells [84]. This provides another promising pathway for therapeutic intervention targeting the apoptotic regulation of CSCs.

Another promising molecular target to promote apoptosis in CSCs is nuclear factor κB (NFκB). NFκB is a transcription factor believed to be intricately involved in the development and progression of certain cancer types [85]. Nuclear factor nB (NFnB), a cousin of NFκB, is an anti-apoptotic transcription factor that is activated in leukemias [86, 87], pancreatic adenocarcinoma [88], and melanoma [89]. Although these nuclear factors are not as well studied as Akt, they may offer promising drug targets. NF-κB inhibitors include NPI-0052 (salinosporamides A), which is in phase I clinical trials, and TDZD-8 (parthenolide), which is still in preclinical testing.

5.4. The Microenvironment and CSCs. Oxygen is a well-known radiosensitizing agent due to its ability to form radiation-induced reactive oxygen species that can damage DNA. Accordingly, radioresistance in breast CSCs may be mediated by increased production of free-radical scavengers [37]. Considering the dependence of radiotherapy on oxygen free radicals, it has long been postulated that areas of low oxygen tension within tumors create microenvironments that are relatively protected from radiation-induced damage [44]. Unexpectedly, it was discovered that CSCs reside along perivascular areas [90] and are thus likely to be well oxygenated [15]. This may help explain the efficacy of antiangiogenic therapies such as bevacizumab in that such therapies may be CSC-specific. Theoretically, CSC compartment hypoxia may be induced by antiangiogenic therapies, conferring radioresistance to the CSCs, although this has yet to be demonstrated in vivo, and the clinical significance of this remains unknown. Still, we speculate that radiation might be more effective in treating cancer if it is administered before any antiangiogenic chemotherapies are applied.

Vermeulen and colleagues recently discovered another interesting role of the microenvironment, specifically in the promotion of cancer cell stemness. They found that high Wnt pathway signaling functionally defines colon CSCs [91]. Importantly, Wnt signaling in these cells depended on costimulation by c-Met signaling. Activated myofibroblasts in the tumor microenvironment were responsible for c-Met activation through production of hepatocyte growth factor (HGF) [91]. Thus, inhibition of stromal-produced HGF or the subsequent activation of c-Met signaling via c-Met inhibitors may represent additional approaches to target CSCs [92].
6. Induction Therapy May Enrich CSCs

An important result of the well-documented CSC resistance to radiation and chemotherapy is that these therapies often serve to enrich the resistant CSC subpopulation, perhaps even selecting for more resistant clones within a heterogeneous CSC population. Evidence of radiation-induced enrichment has been shown in both brain [15, 45] and breast [42] CSCs. Furthermore, radiation has little effect on the ability of remaining CSCs to regrow tumors [15]. Thus, CSC enrichment may be the basis for the relative inability of most single modality cancer treatment strategies to control long-term cancer growth. This pattern of initial response followed by long-term failure is known as “the paradox of response and survival in cancer therapeutics” [93]. CSC-specific pharmaceutical interventions are being developed that may eliminate both primary and acquired CSC chemoresistance. This may dramatically improve the treatment of cancer by abrogating the potential for CSC-induced tumor regrowth and systemic disease spread after initial treatment. For example, in experiments by Sung et al. showing that pancreatic CSCs could survive and expand after serial exposures to gemcitabine, this chemoresistance was overcome by the use of CD44 or ABC transporter inhibitors [94].

Additional strategies to overcome therapeutic resistance during cancer treatment are as follows.

6.1. Concurrent Therapy: The Key to CSC Eradication. It is now well established that combination therapy helps prevent the development of cancer resistance, except in a select group of cancer types where a single pharmaceutically correctable mutation exists [95]. For example, many clinical trials have shown improvements in cancer survival with the use of concurrent chemo- and radiation therapy [96]. This likely reflects the broadly held belief that the best chance for curing cancer is during the first round of therapy before the selection pressure promotes the evolution of resistant CSCs. In later rounds of therapy, not only has the cancer had time to grow and spread further, but it has also evolved resistance to...
previously encountered therapies. Unfortunately, coadministration of chemotherapy and radiation therapy is not effective against all types of cancer, and it is not always feasible due to its potential significant toxicity. Thus, it will be important to design preclinical studies and clinical trials that evaluate potential synergistic benefits of adding CSC-targeted therapies to traditional cancer regimens.

6.2. Surgical Resection Following Induction. As new data supports a role for the CSC hypothesis in solid tumors in addition to hematologic malignancies, outcomes following the surgical resection of solid tumors may significantly improve. If induction approaches can be effectively augmented with anti-CSC therapies, then followup surgical resection may show improved curative outcomes. Theoretically, CSC-specific induction chemotherapies should offer an immediate reduction in CSC metastatic potential and should reduce any hematogenous and lymphatic CSC micrometastases that would otherwise diminish the efficacy of surgical resection. Considering its powerful therapeutic potential, CSC-targeted therapies may be particularly valuable in surgically challenging malignancies such as pancreatic [97] and brain [98] cancer.

6.3. Targeting CSCs. In order to more effectively target CSCs, molecular proliferation and survival mechanisms of CSCs must be better understood. Many institutions have developed large banks of malignant tissues with coordinated clinical data, and this resource is being actively mined. Techniques for concentrating, isolating, and enriching CSCs from resected tumors are also rapidly evolving, and cell culture and xenograft models that allow us to transplant and sustain CSCs are maturing. Finally, these advances have been translated into the development of several therapeutic opportunities. Here, we will review some of the prominent classes of drugs that will potentially yield clinical benefits in the near future. An update of clinical trials assessing these targets is illustrated in Table 1 (data from http://clinicaltrials.gov/).

6.3.1. Wnt Inhibitors. Developmental pathways that direct the differentiation of normal stem cells represent attractive targets for drug discovery. In particular, the roles of Notch and Wnt/β-catenin [99] signaling have been examined, and both have been implicated in the development and progression of several types of leukemia [100, 101]. For instance, Wnt signaling serves an important role in
promoting the proliferation of immature thymocytes [102]. The nonsteroidal anti-inflammatory drug (NSAID) etodolac inhibits Wnt signaling and may be of benefit in the treatment of chronic lymphocytic leukemia [101]. In fact, all NSAIDS may have anti-Wnt properties and thus potentially have anticancer properties [99].

The Wnt/β-catenin pathway promotes genomic instability and DNA damage tolerance that may be enhanced by DNA damage in CSCs [15]. The pathway has been shown to promote genomic instability in colon cancer [103] and possibly promotes conversion of normal stem cells to CSCs in gliomas [104]. Moreover, it has been shown that high Wnt activity defines colon CSCs [91]. It has been postulated that the Wnt/β-catenin pathway may promote genomic instability after irradiation, thus allowing tumor cells to both survive after irradiation and to develop additional adaptive mutations. Wnt inhibitors have been designed to therapeutically prevent this possibility and include ICG-001, fungal derivatives PKF115-854 and CGP049090, as well as monoclonal antibodies against Wnt-1 and Wnt-2 [105] (Figure 3).

6.3.2. Notch Inhibitors. The Notch/γ-secretase/Jagged signaling pathway is an important regulator of differentiation and helps control cell fate [106]. The Notch ligands, Jagged 1 & 2 and Delta1 (D1) to Delta3 (D3), induce the release of the Notch intracellular (Notch-IC) domain via enzymatic proteolytic cleavage by α- and γ-secretases. Notch-IC translocates to the nucleus where it induces transcription of Notch responsive genes [106, 107]. Notch signaling pathways are activated in both breast CSCs [108] and in endothelial cells [109] in response to radiation. Inhibition of Notch signaling via γ-secretase inhibitors can potentially block CSC self-renewal and decrease medulloblastoma growth [110], and significant efforts to downregulate Notch signaling are underway [111]. Currently available Notch signaling inhibitors include MK-0752, a γ-secretase inhibitor that is in clinical development for the treatment of leukemia (Figure 4).

In addition to the classical Notch pathway, other routes may be used to modulate the carcinogenic potential of elevated Notch signaling in CSCs. In particular, the Delta/Notch-like epidermal growth factor-related receptor (DNER) can be induced by histone deacetylase inhibition to inhibit the growth of and induce the differentiation of Glioblastoma neurospheres and xenografts [112]. This provides a basis for the manipulation of noncanonical signaling pathways for therapeutic intervention against CSCs.

6.3.3. Hedgehog Inhibitors. The hedgehog signaling pathway may represent an important modulator of CSC carcinogenesis with significant therapeutic implications [113–117]. Similar to Notch signaling, hedgehog signaling may also benefit from expanded drug discovery efforts within noncanonical pathways [118]. Already, hedgehog inhibitors have been shown to inhibit medulloblastoma growth in mice [119], and
at least 3 different hedgehog inhibitors have reached phase I clinical trials (Figure 5).

6.3.4. Targeting the CSC Marker CD133. As mentioned previously, the cell-surface molecule CD133 is believed to be a stem cell marker for multiple cancer types [51]. Its tumor-initiating function has been demonstrated in CNS cancer, where only CD133+ cells from brain tumor biopsy samples were able to reform tumors in vivo mouse models [120]. A recent study by Wang et al. demonstrated the potential therapeutic use of targeting CD133 to direct therapy specifically towards CSCs. They conjugated single-walled carbon nanotubes (SWNTs), which allow localized hyperthermia treatment, to anti-CD133 monoclonal antibodies, and cultured these products with both CD133+ and CD133− glioblastoma (GBM) cells. A mixture of CD133+ and CD133− cells were then exposed to near-infrared laser light, and the CD133+ GBM cells were selectively destroyed. They found in vivo benefits of this technique as well in mouse models [121].

7. Concluding Remarks

With the advent of multidisciplinary approaches to cancer therapy, significant strides have been made in the treatment of cancer. Now with new discoveries relating to CSCs, we have yet another mechanism of therapeutic arsenal that may prove beneficial in combination with current therapeutic modalities. The basic foundations for CSC-targeted therapy are actively being discovered, and there are already several pharmacologic agents available that are capable of specifically modulating CSC intracellular signaling. Still, much remains unknown about the basic signaling mechanisms of CSCs that confer resistance to treatment, and better methods for the disruption of CSC signaling must be developed to fully integrate the CSC hypothesis into our treatment paradigms. Interestingly, CSCs may not necessarily need to be eradicated to prevent cancer progression if they can be forced to differentiate down their lineage en masse as they do in the treatment of APLM. It is important for future studies to focus on the discovery of new molecular targets for the development of better pharmacological agents to eliminate or differentiate CSCs and that these agents be studied in tandem with traditional cancer therapies.

References

[1] L. Gianni, W. Eiermann, V. Semiglazov et al., “Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort,” The Lancet, vol. 375, no. 9712, pp. 377–384, 2010.
[2] M. Spielmann, H. Roché, T. Delozier et al., “Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial,” Journal of Clinical Oncology, vol. 27, no. 36, pp. 6129–6134, 2009.
[3] G. F. Fleming, M. W. Sill, K. M. Darcy et al., “Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 116, no. 1, pp. 15–20, 2010.
[4] S. Kopetz, P. M. Hoff, J. S. Morris et al., “Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance,” Journal of Clinical Oncology, vol. 28, no. 3, pp. 453–459, 2010.
[5] R. T. Penson, D. S. Dizon, S. A. Cannistra et al., “Phase II study of caroboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced Mullerian tumors,” Journal of Clinical Oncology, vol. 28, no. 1, pp. 154–159, 2010.
[6] M. S. Kies, F. C. Holsinger, J. J. Lee et al., “Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial,” Journal of Clinical Oncology, vol. 28, no. 1, pp. 8–14, 2010.
[7] M. de Lima, R. E. Champlin, P. F. Thall et al., “Phase II/I study of gemtuzumab ozogamicin added to fludarabine, melfalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome,” Leukemia, vol. 22, no. 2, pp. 258–264, 2008.
[8] A. Candoni, G. Martinelli, E. Toffoletti et al., “Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years,” Leukemia Research, vol. 32, no. 12, pp. 1800–1808, 2008.
[9] J. E. Chang, P. M. Voorhees, J. M. Kolesar et al., “Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study,” Hematological Oncology, vol. 27, no. 1, pp. 11–16, 2009.
[10] D. Bhojwani, N. Moskowitz, E. A. Raetz, and W. L. Carroll, “Potential of gene expression profiling in the management of childhood acute lymphoblastic leukemia,” Pediatric Drugs, vol. 9, no. 3, pp. 149–156, 2007.
[11] C. Thirukumaran and D. G. Morris, “Oncolytic viral therapy using reovirus,” Methods in Molecular Biology, vol. 542, pp. 607–634, 2009.
[12] E. J. Kort, N. Paneth, and G. F. Vande Woude, “The decline in U.S. cancer mortality in people born since 1925,” Cancer Research, vol. 69, no. 16, pp. 6500–6505, 2009.
[13] A. Jemal, R. Siegel, E. Ward et al., “Cancer statistics, 2008,” CA: Cancer Journal for Clinicians, vol. 58, no. 2, pp. 71–96, 2008.
[14] T. Lapidot, C. Sirard, J. Vormoor et al., “A cell initiating human acute myeloid leukemia after transplantation into SCID mice,” Nature, vol. 367, no. 6464, pp. 645–648, 1994.
[15] C. E. Eyler and J. N. Rich, “Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis,” Journal of Clinical Oncology, vol. 26, no. 17, pp. 2839–2845, 2008.
[16] J. O. Dalera, R. W. Cho, and M. F. Clarke, “Cancer stem cells: models and concepts,” Annual Review of Medicine, vol. 58, pp. 267–284, 2007.
[17] N. Barker, R. A. Ridgway, J. H. Van Es et al., “Crypt stem cells in the cells-of-origin of intestinal cancer,” Nature, vol. 457, no. 7229, pp. 608–611, 2009.
[18] L. Zhu, P. Gibson, D. S. Currie et al., “Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation,” Nature, vol. 457, no. 7229, pp. 603–607, 2009.
[19] M. Pérez-Caro, C. Cobaleda, I. González-Herrero et al., “Cancer induction by restriction of oncogene expression to
the stem cell compartment,” *EMBO Journal*, vol. 28, no. 1, pp. 8–20, 2009.

[20] J. M. Rosen and C. T. Jordan, “The increasing complexity of the cancer stem cell paradigm,” *Science*, vol. 324, no. 5935, pp. 1670–1673, 2009.

[21] P. N. Kelly, A. Dakic, J. M. Adams, S. L. Nutt, and A. Strasser, “Tumor growth need not be driven by rare cancer stem cells,” *Science*, vol. 317, no. 5836, p. 337, 2007.

[22] D. Bonnet and J. E. Dick, “Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell,” *Nature Medicine*, vol. 3, no. 7, pp. 730–737, 1997.

[23] H. D. Hemmati, I. Nakano, J. A. Lazareff et al., “Cancerous stem cells can arise from pediatric brain tumors,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 25, pp. 15178–15183, 2003.

[24] M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison, and M. F. Clarke, “Prospective identification of tumorigenic breast cancer cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 7, pp. 3983–3988, 2003.

[25] L. Ricci-Vitiani, D. G. Lombardi, E. Pilozzi et al., “Identification and expansion of human colon-cancer-initiating cells,” *Nature*, vol. 445, no. 7123, pp. 111–115, 2007.

[26] M. E. Prince, R. Sivanandan, A. Kaczorowski et al., “Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 3, pp. 973–978, 2007.

[27] A. Eramo, F. Lotti, G. Sette et al., “Identification and expansion of the tumorigenic lung cancer stem cell population,” *Cell Death and Differentiation*, vol. 15, no. 3, pp. 504–514, 2008.

[28] S. Ma, K. W. Chan, and X.-Y. Guan, “In search of liver cancer stem cells,” *Stem Cell Reviews*, vol. 4, no. 3, pp. 179–192, 2008.

[29] T. Schatton, G. F. Murphy, N. Y. Frank et al., “Prospective identification of tumorigenic acute myeloid leukemia: past, present and future,” *Cancer Research*, vol. 67, no. 1, pp. 1–5, 2007.

[30] C. A. O’Brien, A. Pollett, S. Gallinger, and J. E. Dick, “A cancer stem cell paradigm: controversial or just misunderstood?” *Cell Stem Cell*, vol. 4, no. 3, pp. 203–205, 2009.

[31] E. Vlashi, W. H. McBride, and F. Pajonk, “Radiation responses of cancer stem cells,” *Journal of Cellular Biochemistry*, vol. 108, no. 2, pp. 339–342, 2009.

[32] L. Ailles and M. Prince, “Cancer stem cells in head and neck squamous cell carcinoma,” *Methods in Molecular Biology*, vol. 568, pp. 161–173, 2009.

[33] R. J. Winsquist, D. M. Boucher, M. Wood, and B. F. Furey, “Targeting cancer stem cells for more effective therapies: taking out cancer’s locomotive engine,” *Biochemical Pharmacology*, vol. 78, no. 4, pp. 326–334, 2009.

[34] E. Garcia, P. Naveilhan, F. Berger, and D. Wion, “Cancer stem cells: beyond Koch’s postulates,” *Cancer Letters*, vol. 278, no. 1, pp. 3–8, 2009.

[35] J. M. Adams and A. Strasser, “Is tumor growth sustained by rare cancer stem cells or dominant clones?” *Cancer Research*, vol. 68, no. 11, pp. 4018–4021, 2008.

[36] M. V. Blagosklonny, “Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance,” *Cell Cycle*, vol. 4, no. 12, pp. 1693–1698, 2005.

[37] E. Vlashi, W. H. McBride, and F. Pajonk, “Radiation responses of cancer stem cells,” *Journal of Cellular Biochemistry*, vol. 108, no. 2, pp. 339–342, 2009.

[38] G. Guenechea, O. I. Gan, C. Dorrell, and J. E. Dick, “Distinct classes of human stem cells that differ in proliferative and self-renewal potential,” *Nature Immunology*, vol. 2, no. 1, pp. 75–82, 2001.

[39] K. J. Hope, L. Jin, and J. E. Dick, “Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity,” *Nature Immunology*, vol. 5, no. 7, pp. 738–743, 2004.

[40] C. T. Jordan, “Cancer stem cells: controversial or just misunderstood?” *Cell Stem Cell*, vol. 4, no. 3, pp. 203–205, 2009.

[41] G. Lorusso and C. Ruegg, “The tumor microenvironment and its contribution to tumor evolution toward metastasis,” *Histochemistry and Cell Biology*, vol. 130, no. 6, pp. 1091–1103, 2008.

[42] W. A. Woodward, M. S. Chen, F. Behbod, M. P. Alfaro, T. A. Buchholz, and J. M. Rosen, “WNT/β-catenin mediates radiation resistance of mouse mammary progenitor cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 2, pp. 618–623, 2007.

[43] S.-H. Chiou, C.-L. Kao, Y.-W. Chen et al., “Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor,” *PLoS One*, vol. 3, no. 5, Article ID e2090, 2008.

[44] M. Diehn, R. W. Cho, N. A. Lobo et al., “Association of reactive oxygen species levels and radioresistance in cancer stem cells,” *Nature*, vol. 458, no. 7239, pp. 780–783, 2009.

[45] E. R. Blazek, J. L. Foutch, and G. Maki, “Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia,” *International Journal of Radiation Oncology Biology Physics*, vol. 67, no. 1, pp. 1–5, 2007.

[46] G.-B. Zhou, J. Zhang, Z.-Y. Wang, S.-J. Chen, and Z. Chen, “Treatment of acute promyelocytic leukemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy,” *Philosophical Transactions of the Royal Society of London*, vol. 362, no. 1482, pp. 959–971, 2007.

[47] K. Petrie, A. Zelent, and S. Waxman, “Differentiation therapy of acute myeloid leukemia: past, present and future,” *Current Opinion in Hematology*, vol. 16, no. 2, pp. 84–91, 2009.

[48] A. Yagui-Beltrán, B. He, and D. M. Jablons, “The role of cancer stem cells in neoplasia of the lung: past, present and future,” *Clinical & Translational Oncology*, vol. 10, no. 11, pp. 719–725, 2008.

[49] C. A. O’Brien, A. Pollett, S. Gallinger, and J. E. Dick, “A human colon cancer cell capable of initiating tumour growth in immunodeficient mice,” *Nature*, vol. 445, no. 7123, pp. 106–110, 2007.

[50] P. Dalerba, S. J. Dylla, L.-K. Park et al., “Phenotypic characterization of human colorectal cancer stem cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 24, pp. 10158–10163, 2007.

[51] I. Neuzil, M. Stantic, R. Zobalova et al., “Tumour-initiating cells vs. cancer stem cells and CD133: what’s in the name?” *Biochemical and Biophysical Research Communications*, vol. 355, no. 4, pp. 855–859, 2007.

[52] K. Matsumoto, T. Arao, K. Tanaka et al., “mTOR signal and hypoxia-inducible factor-1α regulate CD133 expression in cancer cells,” *Cancer Research*, vol. 69, no. 18, pp. 7160–7164, 2009.

[53] S. A. Benitah, M. Frye, M. Glogauer, and F. M. Watt, “Stem cell depletion through epidermal deletion of Rac1,” *Science*, vol. 309, no. 5736, pp. 933–935, 2005.
A. Blair, D. E. Hogge, L. E. Ailles, P. M. Lansdorp, and H. J. Sutherland, “Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo,” Blood, vol. 89, no. 9, pp. 3104–3112, 1997.

E. Passegué, C. H. M. Jamieson, L. E. Ailles, and I. L. Weissman, “Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, supplement 1, pp. 11842–11849, 2003.

T. Kondo, T. Setoguchi, and T. Taga, “Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 3, pp. 781–786, 2004.

L. Patrawala, T. Calhoun, R. Schneider-Broussard, J. Zhou, M. Stevenson, W. Mostertz, C. Acharya, T. Kondo, T. Setoguchi, and T. Taga, “Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 3, pp. 781–786, 2004.

S. Bao, Q. Wu, R. E. McLendon et al., “Glioma stem cells promote radioresistance by preferential activation of the DNA damage response,” Nature, vol. 429, no. 6992, pp. 413–418, 2004.

M. A. Blasco, “Telomeres and human disease: ageing, cancer and beyond,” Nature Reviews Genetics, vol. 6, no. 8, pp. 611–622, 2005.

E. Estey, G. Garcia-Manero, A. Ferrajoli et al., “Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia,” Blood, vol. 107, no. 9, pp. 3469–3473, 2006.

W. H. Miller Jr., H. M. Schipper, J. S. Lee, J. Singer, and S. Waxman, “Mechanisms of action of arsenic trioxide,” Cancer Research, vol. 62, no. 14, pp. 3893–3903, 2002.

Z. G. Dikmen, G. C. Gellert, S. Jackson et al., “In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor,” Cancer Research, vol. 65, no. 17, pp. 7866–7873, 2005.

R. H. Vonderheide, S. M. Domchek, J. L. Schultz, J. E. Park, S. A. Huber, J. A. King, and S. A. Scher, “Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes,” Clinical Cancer Research, vol. 10, no. 3, pp. 828–839, 2004.

G. H. Danet-Desnoyers, J. L. Luongo, D. A. Bonnet, S. M. Domchek, and R. H. Vonderheide, “Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients,” Experimental Hematology, vol. 33, no. 11, pp. 1275–1280, 2005.

M. Dean, “ABC transporters, drug resistance, and cancer stem cells,” Journal of Mammary Gland Biology and Neoplasia, vol. 14, no. 1, pp. 3–9, 2009.

L. Gatti, G. L. Beretta, G. Cossa, F. Zunino, and P. Pereggi, “ABC transporters as potential targets for modulation of drug resistance,” Mini-Reviews in Medicinal Chemistry, vol. 9, no. 9, pp. 1102–1112, 2009.

D. Hambardzumyan, O. J. Becher, M. K. Rosenblum, P. P. Pandolfi, K. Manova-Todorova, and E. C. Holland, “P13K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo,” Genes and Development, vol. 22, no. 4, pp. 436–448, 2008.

G. Rao, C. A. Pedone, L. D. Valle, K. Reiss, E. C. Holland, and D. W. Fults, “Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice,” Oncogene, vol. 23, no. 36, pp. 6156–6162, 2004.

S. Ma, T. K. Lee, B.-J. Zheng, K. W. Chan, and X.-Y. Guan, “CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway,” Oncogene, vol. 27, no. 12, pp. 1749–1758, 2008.

D. Hambardzumyan, O. J. Becher, and E. C. Holland, “Cancer stem cells and survival pathways,” Cell Cycle, vol. 7, no. 10, pp. 1371–1378, 2008.

S. Chumsri, W. Matsui, and A. M. Burger, “Therapeutic implications of leukemic stem cell pathways,” Clinical Cancer Research, vol. 13, no. 22, pp. 6549–6554, 2007.

S. Knapper, A. K. Burnett, T. Littlewood et al., “A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy,” Blood, vol. 108, no. 10, pp. 3262–3270, 2006.

X. Saeiens, N. Festjens, L. Vandewalle, M. Van Gurp, G. Van Loo, and P. Vandenberghe, “Toxic proteins released from mitochondria in cell death,” Oncogene, vol. 23, no. 16, pp. 2861–2874, 2004.

E. C. LaCasce, D. J. Mahoney, H. H. Cheung, S. Plenchette, S. Baird, and R. G. Korneluk, “IAP-targeted therapies for cancer,” Oncogene, vol. 27, no. 48, pp. 6252–6275, 2008.

S. H. K. Vellanki, A. Grabrucker, S. Liebau et al., “Small-molecule XIAP inhibitors enhance γ-irradiation-induced apoptosis in glioblastoma,” Neoplasia, vol. 11, no. 8, pp. 743–752, 2009.

F. H. Sarkar, Y. Li, Z. Wang, and D. Kong, “NF-κB signaling pathway and its therapeutic implications in human diseases,” International Reviews of Immunology, vol. 27, no. 5, pp. 293–319, 2008.
myelogenous leukemia cells," Blood, vol. 98, no. 8, pp. 2301–2307, 2001.

[87] U. Kordes, D. Krappmann, V. Heissmeyer, W. D. Ludwig, and C. Scheidereit, “Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells,” Leukemia, vol. 14, no. 3, pp. 399–402, 2000.

[88] W. Wang, J. L. Abbruzzese, D. B. Evans, L. Larry, K. R. Cleary, and P. J. Chiao, “The nuclear factor-xB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells,” Clinical Cancer Research, vol. 5, no. 1, pp. 119–127, 1999.

[89] R. L. Shattuck-Brandt and A. Richmond, “Enhanced degradation of I-κB contributes to endogenous activation of NF-κB in Hs294T melanoma cells,” Cancer Research, vol. 57, no. 14, pp. 3032–3039, 1997.

[90] C. Calabrese, H. Poppleton, M. Kocak et al., “A perivascular niche for brain tumor stem cells,” Cancer Cell, vol. 11, no. 1, pp. 69–82, 2007.

[91] L. Vermeulen, F. De Sousa E Melo, M. Van Der Heijden et al., “Wnt activity defines colon cancer stem cells and is regulated by the microenvironment,” Nature Cell Biology, vol. 12, no. 5, pp. 468–476, 2010.

[92] H. Korkaya and M. S. Wicha, “Cancer stem cells: nature versus nurture,” Nature Cell Biology, vol. 12, no. 5, pp. 419–421, 2010.

[93] C. A. Huff, W. Matsui, B. D. Smith, and R. J. Jones, “The paradox of response and survival in cancer therapeutics,” Blood, vol. 107, no. 2, pp. 431–434, 2006.

[94] P. H. Sung, J. Wen, S. Bang, S. Park, and S. Y. Song, “CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells,” International Journal of Cancer, vol. 125, no. 10, pp. 2323–2331, 2009.

[95] J. C. Becker, S. Ugurel, and D. Schrama, “Strategies to optimize the use of targeted agents for tumor therapy,” Journal of the German Society of Dermatology, vol. 6, no. 4, pp. 281–286, 2008.

[96] J. Bernier, “Current state-of-the-art for concurrent chemoradiation,” Seminars in Radiation Oncology, vol. 19, no. 1, pp. 3–10, 2009.

[97] E. A. Newman, D. M. Simeone, and M. W. Mulholland, “Adjuvant treatment strategies for pancreatic cancer,” Journal of Gastrointestinal Surgery, vol. 10, no. 6, pp. 916–926, 2006.

[98] J.-M. Liu, B.-Y. Mao, S. Hong, Y.-H. Liu, and X.-J. Wang, “The postoperative brain tumour stem cell (BTSC) niche and cancer recurrence,” Advances in Therapy, vol. 25, no. 5, pp. 389–398, 2008.

[99] N. Barker and H. Clevers, “Mining the Wnt pathway for cancer therapeutics,” Nature Reviews Drug Discovery, vol. 5, no. 12, pp. 997–1014, 2006.

[100] F. Weerkamp, J. M. van Dongen, and F. J. T. Staal, “Notch and Wnt signaling in T-lymphocyte development and acute lymphoblastic leukemia,” Leukemia, vol. 20, no. 7, pp. 1197–1205, 2006.

[101] D. Lu, Y. Zhao, R. Tawatao et al., “Activation of the Wnt signaling pathway in chronic lymphocytic leukemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 9, pp. 3118–3123, 2004.

[102] F. J. T. Staal and H. C. Clevers, “WNT signalling and haematopoiesis: a WNT-WNT situation,” Nature Reviews Immunology, vol. 5, no. 1, pp. 21–30, 2005.

[103] M. V. Hadjiananis, M. Brückner, B. Jerchow, W. Birchmeier, W. Dietmaier, and J. Behrens, “Aberant Wnt/β-catenin signaling can induce chromosomal instability in colon cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 28, pp. 10747–10752, 2006.

[104] A. Shiras, S. Chettiar T, V. Shepal, G. Rajendran, G. R. Prasad, and P. Shastry, “Spontaneous transformation of human adult nontumorigenic stem cells to cancer stem cells is driven by genomic instability in a human model of glioblastoma,” Stem Cells, vol. 25, no. 6, pp. 1478–1489, 2007.

[105] R. W. C. Pang and R. T. P. Poon, “From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now,” Oncology, vol. 72, supplement 1, pp. 30–44, 2007.

[106] S. Arvanitis-Tskonas, M. D. Rand, and R. J. Lake, “Notch signaling: cell fate control and signal integration in development,” Science, vol. 284, no. 5415, pp. 770–776, 1999.

[107] S. M. Lehar, J. Dooley, A. G. Farr, and M. J. Bevan, “Notch ligands delta1 and jagged1 transmit distinct signals to T-cell precursors,” Blood, vol. 105, no. 4, pp. 1440–1447, 2005.

[108] T. M. Phillips, W. H. McBride, and F. Pajonk, “The response of CD24-/low/CD44+ breast cancer-initiating cells to radiation,” Journal of the National Cancer Institute, vol. 98, no. 24, pp. 1777–1785, 2006.

[109] M. Scharpfenecker, J. J. C. M. Kruse, D. Sprong, N. S. Russell, P. ten Dijke, and F. A. Stewart, “Ionizing radiation shifts the PAl/-ID-1 balance and activates notch signaling in endothelial cells,” International Journal of Radiation Oncology Biology Physics, vol. 73, no. 2, pp. 506–513, 2009.

[110] X. Fan, W. Matsui, L. Khaki et al., “Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors,” Cancer Research, vol. 66, no. 15, pp. 7445–7452, 2006.

[111] V. Bolós, M. Blanco, V. Medina, G. Aparicio, S. Díaz-Prado, and E. Grande, “Notch signalling in cancer stem cells,” Clinical and Translational Oncology, vol. 11, no. 1, pp. 11–19, 2009.

[112] P. Sun, S. Xia, B. Lal et al., “DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation,” Stem Cells, vol. 27, no. 7, pp. 1473–1486, 2009.

[113] V. Medina, M. B. Calvo, S. Díaz-Prado, and J. Espada, “Hedgehog signalling as a target in cancer stem cells,” Clinical and Translational Oncology, vol. 11, no. 4, pp. 199–207, 2009.

[114] M. Lauth and R. Toftgård, “The Hedgehog pathway as a drug target in cancer therapy,” Current Opinion in Investigational Drugs, vol. 8, no. 6, pp. 457–461, 2007.

[115] G. V. Borzillo and B. Lippa, “The Hedgehog signaling pathway as a target for anticancer drug discovery,” Current Topics in Medicinal Chemistry, vol. 5, no. 2, pp. 147–157, 2005.

[116] J. Jiang and C.-C. Hui, “Hedgehog signaling in development and cancer,” Developmental Cell, vol. 15, no. 6, pp. 801–812, 2008.

[117] S. J. Scales and F. J. de Sauvage, “Mechanisms of Hedgehog pathway activation in cancer and implications for therapy,” Trends in Pharmacological Sciences, vol. 30, no. 6, pp. 303–312, 2009.

[118] D. Jenkins, “Hedgehog signalling: emerging evidence for non-canonical pathways,” Cellular Signalling, vol. 21, no. 7, pp. 1023–1034, 2009.

[119] D. M. Berman, S. S. Karhadkar, A. R. Hallahan et al., “Medulloblastoma growth inhibition by Hedgehog pathway blockade,” Science, vol. 297, no. 5586, pp. 1559–1561, 2002.

[120] S. K. Singh, C. Hawkins, I. D. Clarke et al., “Identification of human brain tumour initiating cells,” Nature, vol. 432, no. 7015, pp. 396–401, 2004.
[121] C. H. Wang, S. H. Chiou, C. P. Chou, Y. C. Chen, Y. J. Huang, and C. A. Peng, "Photothermolysis of glioblastoma stemlike cells targeting by carbon nanotubes conjugated with CD133 monoclonal antibody," *Nanomedicine: Nanotechnology, Biology and Medicine*. In press.